Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Man! Interest In This Stock Is Jumping!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Jul 17, 2021 7:09pm
114 Views
Post# 33565756

RE:RE:RE:RE:RE:RE:Man! Interest In This Stock Is Jumping!

RE:RE:RE:RE:RE:RE:Man! Interest In This Stock Is Jumping!There is no interest in bioasis because there is zero confidence in DR. Period.

craigheny.  Howsit going.  Long time.  I'd be surprised if BTI gets above a buck in the next few years but I don't see it as DR's fault at all.  I think she has been doing the best she could given the lack of funding.  If she had the cash I'm sure she would have moved 001 into a clinical trial by now. Hopefully the recent infusion of cash will help us along. Be careful what you wish for.  If she left, we could easily end up with a CEO who moves this forward by wiping out existing shareholders.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities